Jia Tong et al.47have found that RBM39 was overexpressed in myeloma cells and associated with poor prognosis of patients, and they demonstrated that the α‐DARS‐AS1‐RBM39 axis of HIF‐1 is a potential target for the treatment of multiple myeloma. Here, RBM39 is linked to plasma cell myeloma.